Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 334

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 334
---
   |     |              |         2.75 |   |
| Weighted-average discount rate for operating leases                  |     |            |          9.60 | % |     |              |         9.60 | % |

<div align='center'>F-14</div>

The following table reconciles the undiscounted
future minimum lease payments (displayed by year and in the aggregate) under non-cancelable operating leases with terms of more than
one year to the total operating lease liabilities recognized on the Company’s condensed consolidated balance sheets as of September
30, 2024:

Maturity of the Company’s lease liabilities
as of September 30, 2024:

| Remainder of 2024       |     | $ |   168,133 |   |
| 2025                    |     |   |   990,055 |   |
| 2026                    |     |   |   726,394 |   |
| Total lease payments    |     |   | 1,884,582 |   |
| Less: imputed interest  |     |   |  (182,034 | ) |
| Total lease liabilities |     | $ | 1,702,548 |   |

NOTE 7 – STOCKHOLDERS’ DEFICIT

Successor Series A Convertible Preferred Stock

The Company designated 12,580 shares of its authorized
preferred stock as the Series A Preferred Stock and the rights, preferences and privileges of the Series A Preferred Stock are summarized
below.

Each share of Series A Preferred Stock has a
stated value of $1,000 per share and, when issued, the Series A Preferred Stock was fully paid and non-assessable. The Series A Preferred
Stock, ranks senior to all other Company capital stock unless required holder votes are obtained to create a class of stock senior to
Series A Preferred Stock. The requisite holders of Series A Preferred Stock consented to the issuance of the Series C Preferred Stock
described below, which ranks senior to the Series A Preferred Stock and Series B Preferred Stock.

Dividend and Participation Rights: The
holders of Series A Preferred Stock will be entitled to dividends, on an as-if converted basis, equal to and in the same form as dividends
actually paid on shares of Common Stock, when and if actually paid. Series A Preferred Stockholders will be entitled to participate pro
rata in any purchase rights extended to holders of Common Stock on an as-converted basis.

Conversion